Articles

The TROPION-Lung01 trial found a significant improvement in progression-free survival when comparing Dato-DXd to DTX in patients with advanced non-small cell lung cancer (NSCLC), particularly those with nonsquamous histology. Read More ›

The Explore ALK/ROS study investigated the management practices and clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC) who tested positive for ROS1. Read More ›

A retrospective analysis was performed on deidentified records of patients with metastatic non-small cell lung cancer to assess adherence with the targeted therapy recommendations outlined in the ESMO and NCCN guidelines and to analyze the duration from genomic sequencing to the commencement of targeted treatment. Read More ›

This phase 2 study aimed to assess the efficacy and safety of a combination of pembrolizumab, plinabulin, and docetaxel in patients with metastatic non-small cell lung cancer (NSCLC) who have developed resistance to immunotherapy. Read More ›

The second interim analysis of overall survival from the BEAT-SC trial assessed bevacizumab for its effectiveness and safety in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) in Japan and China. Read More ›

This study evaluated real-world treatments and outcomes of limited disease small cell lung cancer (SCLC) using the Canadian SCLC Database (CASCADE). Read More ›

An ongoing, open-label, single-arm phase 2 study (IFCT-1904) evaluated patients with untreated BRAF V600E-mutant non-small cell lung cancer (NSCLC) who received encorafenib plus binimetinib. Read More ›

Data from phase 2 trials involving lurbinectedin and irinotecan have been analyzed for patients with relapsed small cell lung cancer (SCLC) who have had a chemotherapy-free interval of >30 days. Read More ›

A pooled analysis of 5-year clinical outcomes from 2 early-phase trials, NEOSTAR and CA209-159, showed promising long-term clinical effectiveness in patients with resectable non-small cell lung cancer (NSCLC). Read More ›

At the 2024 European Hematology Association Annual Congress, researchers presented the multilineage and safety results from the COMMANDS trial of transfusion-dependent, erythropoiesis-stimulating agent–naïve patients with very low-, low-, or intermediate-risk myelodysplastic syndromes. Read More ›